Please assess the completion status of the following clinical trial:

Trial Title: This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female aged 18 to 65 years and in good general health~* Moderate to severe AD for at least 6 months prior to Randomization~* History of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable~* EASI score ≥ 16 at Screening and at Randomization~* vIGA AD score ≥ 3 at Screening and at Randomization~* AD involved BSA ≥ 10% at Screening and at Randomization~Key Exclusion Criteria:~* Any factors that in the Investigator's opinion would predispose the subject to develop an infection~* Known or suspected congenital or acquired immunodeficiency state, or condition that would compromise the subject's immune status~* Not able to tolerate SC drug administration~* Tanning booth use or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks before Randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ANB032 SC Dose 1 (Type: EXPERIMENTAL): This arm will receive treatment SC
- ANB032 SC Dose 2 (Type: EXPERIMENTAL): This arm will receive treatment SC
- ANB032 SC Dose 3 (Type: EXPERIMENTAL): This arm will receive treatment SC
- Placebo (Type: PLACEBO_COMPARATOR): This arm will receive Placebo SC

Based on this trial design, predict the completion outcome and termination type (if applicable).